250B MC company a bit of a stretch? Most likely. Able to generate that value in revenue? Almost certainly, IF both cardioprotection and FTO go for full indications/mass adoption in best case scenarios science wise. (well aware that is a massive IF!)
With the new formulation providing a reset patent runway, early approval via breakthrough drug pathway could have Zantrene earning top dollar for longer.
In the Keytruda chart above, total sales for 9 years adds up to US$79.86B. It’s worth keeping in mind that if a simple 18% royalty was paid out on those figures, 9 year earnings would be US$14.37B. Wonder what the SP would be on a company generating that sort of $$?
General Comments / Chat, page-7340
-
- There are more pages in this discussion • 3,927 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.030(2.10%) |
Mkt cap ! $238.5M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.46 | $1.38 | $123.1K | 87.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19987 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 330 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |